Eder Orlando Méndez Salazar

Health Manager of the Clinical Laboratory, Red Cross Hospital, Coatzacoalcos, Mexico, 01/2010, 12/2015

• Postdoctoral Fellowship Award, Montreal Cancer Institute, 31,000.00 CAD, 2023
• Research grant at CRCHUM, 45,000.00 CAD, 2023-2024
• Doctoral Fellow Program, National Autonomous University of Mexico, 750,000.00 MXN, 2023
• Doctoral Mobility Scholarship abroad, 3,134.05 €, 2023

American Society for Nutrition (ASN), Member, 01/2016, present

• Altered gut microbiota and compositional changes in Firmicutes and Proteobacteria in Mexican undernourished and obese children., Méndez-Salazar, E. O., Ortiz-López, M. G., Granados-Silvestre, M. D. L. Á., Palacios-González, B., & Menjivar, M., Frontiers in microbiology, 9, 2494, 2018, 10.1186/s10020-021-00311-5
• Taxonomic variations in the gut microbiome of gout patients with and without tophi might have a functional impact on urate metabolism., Méndez-Salazar, E. O., Vázquez-Mellado, J., Casimiro-Soriguer, C. S., Dopazo, J., Çubuk, C., Zamudio-Cuevas, Martínez-Nava, G. A., Molecular Medicine, 27, 1, 1-13, 2021, 10.1186/s10020-021-00311-5

• Montreal Cancer Institute (Institut du Cancer de Montréal), Volunteer, 01/2022, 12/2024, Participated in various volunteer events aimed at supporting patients and promoting cancer awareness.
• Red Cross (Cruz Roja), Volunteer, 01/2010, 12/2015, Recognized for outstanding contributions to enhancing the quality of human services.

• Dr. Taiki Hakozaki, Postdoctoral Research Collaborator, t-hakozaki@akane.waseda.jp, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital
• Dr. Berenice Palacios González, PhD supervisor, bpalacios@inmegen.gob.mx, National Autonomous University of Mexico (UNAM) at the National Institute of Genomic Medicine (INMEGEN)
• Dr. Gabriela A. Martínez Nava, PhD co-supervisor, ameria.justice@gmail.com, National Rehabilitation Institute 'Luis Guillermo Ibarra Ibarra'

• Metagenomic Analysis of Taxonomic Signatures in the Intestinal Microbiome of Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Immunotherapy and Fecal Microbiota Transplantation (FMT), Conference, 2024, Montreal, Canada
• Phase II trial of fecal microbiota transplantation in combination with ipilimumab and nivolumab in patients with advanced cutaneous melanoma (FMT-LUMINate trial), Poster presentation, 2024, Toronto, Canada

• Postdoctoral Researcher, Research Center of the Université de Montréal Hospital (CRCHUM), Montreal, Quebec, Canada, 10/2022, 09/2024, Investigated the gut microbiome signatures in patients with melanoma and non-small cell lung cancer (NSCLC) treated with immunotherapy and fecal microbiota transplantation (FMT).
• Visiting Researcher, Computational Medicine and Clinical Bioinformatics Laboratory, Virgen del Rocío Hospital, Seville, Spain, 01/2019, 12/2020, Implemented advanced statistical analyses using Python and R Studio, aiming to enhance my skills in data interpretation and biomarker discovery in multi-omics datasets.